Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Filgotinib (Jyseleca®)	TA792: Filgotinib for treating moderately to severely active ulcerative colitis
Finerenone (Kerendia®)	TA877: Finerenone for treating chronic kidney disease in type 2 diabetes	Prescribing to be in line with the prescribing support document. Prescribing guidance (PDF file)
Fingolimod capsules	TA254 - Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
Flourescein sodium 10% injection (10 x 5ml amps)	TA274 - Ranibizumab for treating diabetic macular oedema
Flucinolone acetonide 0.025% ointment	TA85 - Frequency of application of topical corticosteroids for atopic eczema
Flucitasone and salmeterol (Seretide®)	TA138 - Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over	For existing patients, for paediatric use only (i.e. up to 18 years of age) - APC listing of current formulary brands
Fludarabine injection	TA119 - Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia TA29 - Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fludarabine tablets	TA119 - Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia TA29 - Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fludroxycortide 7.5cm x 200cm tape	TA85 - Frequency of application of topical corticosteroids for atopic eczema
Fluocinolone acetonide 0.025% gel	TA85 - Frequency of application of topical corticosteroids for atopic eczema

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.